Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study.
Gerard E FranciscoWolfgang H JostGanesh BavikatteDaniel S BandariSimon F T TangMichael C MuninJoan LargentAubrey M AdamsAleksej ZuzekAlberto EsquenaziPublished in: PM & R : the journal of injury, function, and rehabilitation (2020)
ASPIRE captured the real-world individualized nature of onabotulinumtoxinA utilization for upper limb spasticity over 2 years, with consistently high clinician- and patient-reported satisfaction. Data in this primary analysis will guide clinical use of onabotulinumtoxinA, as well as provide insights to improve educational programs on spasticity management.